Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation.

Vaccine - 26 Jan 2004

Schumacher Reto, Adamina Michel, Zurbriggen Rinaldo, Bolli Martin, Padovan Elisabetta, Zajac Paul, Heberer Michael, Spagnoli Giulio C

Abstract excerpt

Immunopotentiating reconstituted influenza virosomes (IRIV) are one of the few adjuvants currently licensed for human use. While their adjuvant capacity in the induction of humoral responses is clearly documented, few data exist on their effects on T cell immune response. Here we addressed IRIV adjuvance in the induction of HLA class I restricted cytotoxic T lymphocytes (CTL) in vitro. Lymphocyte stimulation with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Centrifugation, Density Gradient

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, MHC Class I

Share to Immunity, Cellular

Share to Influenza A virus

Share to Influenza Vaccines

Share to Liposomes

Share to T-Lymphocytes, Helper-Inducer

Source

Identifiers

PMID: 14741164
DOI: 10.1016/j.vaccine.2003.08.019

Genes

CXCR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation.PMID 14741164Read ↗

TLR7 and RIG-I dual-adjuvant loaded nanoparticles drive broadened and synergistic responses in dendritic cells <i>in vitro</i> and generate unique cellular immune responses in influenza vaccinationSemantic proximity Read ↗

RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockadeSemantic proximity Read ↗

Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine developmentSemantic proximity Read ↗

Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes.Semantic proximity Read ↗

Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice.Semantic proximity Read ↗

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitroSemantic proximity Read ↗

TLR agonists are highly effective at eliciting functional memory CTLs of effector memory phenotype in peptide immunization.Semantic proximity Read ↗

New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Semantic proximity Read ↗

Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo.Semantic proximity Read ↗

Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune ResponsesSemantic proximity Read ↗

The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of AdministrationSemantic proximity Read ↗

Polymeric Pathogen-like Particles-Based Combination Adjuvants Elicit Potent Mucosal T Cell Immunity to Influenza A VirusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.